SlidesetHIVHIV DART and Emerging Viruses 2018Baricitinib reverses HIV associated neurocognitive disorders and reservoir seeding in a SCID mouse model | Christina Gavegnano, PhDView Slideset
SlidesetHIVHIV DART and Emerging Viruses 2018HIV reservoir dynamics: Implications for HIV latency establishment and reversal | Deanna Kulpa, PhDView Slideset
SlidesetHIVTuberculosisHIV DART and Emerging Viruses 2018Gertrude Elion Distinguished Lecturer Award Lecture: Innovation with an Impact: Development of HIV and TB drugs | Paul Stoffels, MDView Slideset
SlidesetHIVHIV DART and Emerging Viruses 2018Understanding barriers to HIV cure | Robert Siliciano, MD, PhDView Slideset
SlidesetHIVHIV DART and Emerging Viruses 2018State of the Art Lecture: Molecular basis for HIV latency | Jonathan Karn, PhDView Slideset
RSRaymond SchinaziPhD, DSc, FAASLDSlidesetHIV DART and Emerging Viruses 2018Opening remarks and presentation of Gertrude Elion Distinguished Lecturer Award | Raymond Schinazi, PhD, DScView Slideset
SlidesetHIV DART and Emerging Viruses 2018Presentation of Gertrude Elion Distinguished Lecturer Award recipient | Rowena Johnston, PhDView Slideset
SlidesetRSVHIV DART and Emerging Viruses 2018Development of protease inhibitors against norovirus and other emerging viruses | Ladislau KovariView Slideset
SlidesetHIVHIV DART and Emerging Viruses 2018Abstract: Rhesus macaque model of SIV/SHIV-Zika co-infection (#9) | Siddappa ByrareddyView Slideset
SlidesetHIVHIV DART and Emerging Viruses 2018Hispanic/Latino longitudinal cohort of HIV-seropositive women and neurological complications | Loyda Melendez, PhDView Slideset
MAMichael AboudMBChBSlidesetHIVHIV DART and Emerging Viruses 2018Abstract: Initial viral load decline and response rates by baseline viral load strata with dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate/emtricitabine: Pooled results from the GEMINI studies (#7) | Michael AboudView Slideset
SlidesetHIVHIV DART and Emerging Viruses 2018Abstract: Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in a rapid initiation model of care for HIV-1 infection: Week 24 interim analysis of the DIAMOND study (#6) | Keith Dunn, PharmD, BCPS, AAHIVEView Slideset
